Why Is PULSE BIOSCIENCES IN (PLSE) Stock Up Today?

Why PLSE stock is up today

Pulse Biosciences stock rose 8.17% to $35.47 in morning trading as Oppenheimer raised its price target for the company following the release of atrial fibrillation data. The move reflects renewed investor confidence in the company’s therapeutic development progress. The stock has traded within a 52-week range of $12.56 to $33.87, and the recent rally pushes it above its previous high.

What Happened

Oppenheimer increased its price target for PLSE based on positive data from the company’s atrial fibrillation program. This upgrade follows recent insider purchases by the CEO and a director, who together bought approximately $13.3 million in shares through an ATM program on May 11. Additionally, Canaccord Genuity initiated coverage on Pulse Biosciences with a Buy rating and a $32 price target. These developments suggest growing institutional and internal support for the stock’s potential. Pulse Biosciences also reported first-quarter earnings of $(0.27) per share, which beat the estimated $(0.32), and revenue of $401,000, exceeding the forecast of $400,000.

What The Data Shows

The stock has traded with a beta of 1.65, indicating higher volatility than the broader market. Despite a market cap of $2.1 billion, the company remains unprofitable with a trailing twelve-month EPS of -1.10. Recent insider activity has been entirely in the form of purchases, with no sell transactions reported in the last 90 days. The stock’s 30-day average sentiment score is 61 out of 100, improving to 67 in the last seven days. This suggests a gradual shift in market perception.

What To Watch

Investors should look ahead to May 4, 2026, when the company is scheduled to report earnings. Coverage breadth will be a key factor to monitor as the stock continues to attract new institutional attention.